Last reviewed · How we verify
AVE1625 B
AVE1625 B is a P2Y13 receptor antagonist that modulates lipid metabolism and reduces apolipoprotein B-containing lipoprotein levels.
AVE1625 B is a novel compound developed by Sanofi for the treatment of atherogenic dyslipidemia in abdominally obese patients. Currently in Phase 2, it has shown promise in early trials but lacks an FDA label. The drug's mechanism targets lipid metabolism, aiming to reduce cardiovascular risk factors.
At a glance
| Generic name | AVE1625 B |
|---|---|
| Sponsor | Sanofi |
| Drug class | P2Y13 receptor antagonist |
| Target | P2Y13 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
AVE1625 B targets the P2Y13 receptor, a G-protein coupled receptor involved in hepatic lipid homeostasis. By antagonizing P2Y13, the drug increases hepatic uptake of apolipoprotein B-containing lipoproteins, thereby lowering LDL cholesterol and triglycerides. This mechanism offers a novel approach to dyslipidemia management independent of statin pathways.
Approved indications
- Dyslipidemia / hypercholesterolemia
Common side effects
- Liver enzyme elevation
- Gastrointestinal disorders